Phase Ib venetoclax combined with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.

Philippe Moreau,Asher Chanan-Khan,Andrew W. Roberts,Amit Agarwal,Thierry Facon,Shaji Kumar,Cyrille Touzeau,Susan Diehl,Jaclyn Cordero,Jeremy A. Ross,Wijith Munasinghe,Ming Zhu,Ahmed Hamed Salem,Joel D. Leverson,Paulo Maciag,Maria Verdugo,Simon J. Harrison

Phase Ib venetoclax combined with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.

2016

Philippe Moreau
Asher Chanan-Khan
Andrew W. Roberts
Amit Agarwal
Thierry Facon
Shaji Kumar
Cyrille Touzeau
Susan Diehl
Jaclyn Cordero
Jeremy A. Ross
Wijith Munasinghe
Ming Zhu
Ahmed Hamed Salem
Joel D. Leverson
Paulo Maciag
Maria Verdugo
Simon J. Harrison

8011Background: BCL-2 and MCL-1 promote multiple myeloma (MM) cell survival. Bortezomib (B) inhibits MCL-1 activity, and venetoclax (VEN), an oral, selective BCL-2 inhibitor, enhances its efficacy ...

Keywords:

Refractory Multiple Myeloma
Dexamethasone
Bortezomib
Oncology
Pathology
Internal medicine
Medicine
Venetoclax
cell survival
Multiple myeloma
relapsed refractory

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations